The Vitrolife Group appoints Pär Ihrskog as the new Chief Financial Officer
Vitrolife Group (VTRLY) has announced the appointment of Pär Ihrskog as their new Chief Financial Officer, effective October 10, 2025. Ihrskog, currently serving as CFO at Bufab Group, brings significant financial expertise from his previous roles, including his position as Group CFO/CIO at Embellence Group and various finance roles at SKF, where he gained international experience in the U.S. and China.
The new CFO holds a master's degree in business administration and will succeed Helena Wennerström, who will continue as acting CFO until Ihrskog assumes the position. CEO Bronwyn Brophy O'Connor expressed confidence that Ihrskog's extensive financial expertise and leadership experience in listed companies will support Vitrolife's strategy for sustainable profitable growth.
Vitrolife Group (VTRLY) ha annunciato la nomina di Pär Ihrskog come nuovo Chief Financial Officer, con effetto dal 10 ottobre 2025. Ihrskog, attualmente CFO presso Bufab Group, porta con sé una significativa esperienza finanziaria derivante dai suoi ruoli precedenti, tra cui quello di CFO/CIO di gruppo presso Embellence Group e vari ruoli finanziari in SKF, dove ha acquisito esperienza internazionale negli Stati Uniti e in Cina.
Il nuovo CFO possiede un master in amministrazione aziendale e succederà a Helena Wennerström, che continuerà a ricoprire il ruolo di CFO ad interim fino all'assunzione di Ihrskog. Il CEO Bronwyn Brophy O'Connor ha espresso fiducia nel fatto che l'ampia esperienza finanziaria e le capacità di leadership di Ihrskog in aziende quotate supporteranno la strategia di Vitrolife per una crescita sostenibile e redditizia.
Vitrolife Group (VTRLY) ha anunciado el nombramiento de Pär Ihrskog como su nuevo Director Financiero, efectivo a partir del 10 de octubre de 2025. Ihrskog, que actualmente se desempeña como CFO en Bufab Group, aporta una significativa experiencia financiera de sus roles anteriores, incluyendo su posición como CFO/CIO del grupo en Embellence Group y varios roles financieros en SKF, donde adquirió experiencia internacional en EE. UU. y China.
El nuevo CFO tiene una maestría en administración de empresas y sucederá a Helena Wennerström, quien continuará como CFO interina hasta que Ihrskog asuma el cargo. La CEO Bronwyn Brophy O'Connor expresó confianza en que la amplia experiencia financiera y el liderazgo de Ihrskog en empresas cotizadas apoyarán la estrategia de Vitrolife para un crecimiento sostenible y rentable.
비트로라이프 그룹 (VTRLY)가 Pär Ihrskog를 새로운 최고재무책임자(CFO)로 임명했다고 발표했습니다. 임기는 2025년 10월 10일부터 시작됩니다. Ihrskog는 현재 Bufab Group에서 CFO로 재직 중이며, Embellence Group의 그룹 CFO/CIO와 SKF에서의 다양한 재무 직책을 포함한 이전 경력에서 상당한 재무 전문성을 갖추고 있습니다. 그는 미국과 중국에서 국제적인 경험을 쌓았습니다.
새로운 CFO는 경영학 석사 학위를 소지하고 있으며, Helena Wennerström의 뒤를 이어 CFO 직무를 맡게 됩니다. Wennerström는 Ihrskog가 직무를 맡을 때까지 임시 CFO로 계속 활동할 것입니다. CEO인 Bronwyn Brophy O'Connor는 Ihrskog의 폭넓은 재무 전문성과 상장 기업에서의 리더십 경험이 비트로라이프의 지속 가능한 수익성 성장 전략을 지원할 것이라고 확신했습니다.
Vitrolife Group (VTRLY) a annoncé la nomination de Pär Ihrskog en tant que nouveau directeur financier, à compter du 10 octobre 2025. Ihrskog, actuellement CFO chez Bufab Group, apporte une expertise financière significative de ses précédents postes, y compris celui de CFO/CIO de groupe chez Embellence Group et divers rôles financiers chez SKF, où il a acquis une expérience internationale aux États-Unis et en Chine.
Le nouveau CFO détient un master en administration des affaires et succédera à Helena Wennerström, qui continuera à exercer en tant que CFO par intérim jusqu'à ce qu'Ihrskog prenne ses fonctions. La PDG Bronwyn Brophy O'Connor a exprimé sa confiance dans le fait que l'expertise financière étendue et l'expérience en leadership d'Ihrskog dans des entreprises cotées soutiendront la stratégie de Vitrolife pour une croissance durable et rentable.
Vitrolife Group (VTRLY) hat die Ernennung von Pär Ihrskog zum neuen Chief Financial Officer bekannt gegeben, die am 10. Oktober 2025 wirksam wird. Ihrskog, der derzeit als CFO bei Bufab Group tätig ist, bringt bedeutende finanzielle Expertise aus seinen vorherigen Positionen mit, darunter seine Rolle als Group CFO/CIO bei Embellence Group sowie verschiedene Finanzpositionen bei SKF, wo er internationale Erfahrungen in den USA und China gesammelt hat.
Der neue CFO hat einen Master-Abschluss in Betriebswirtschaft und wird Helena Wennerström nachfolgen, die bis zur Amtsübernahme von Ihrskog weiterhin als interimistischer CFO tätig sein wird. CEO Bronwyn Brophy O'Connor äußerte sich zuversichtlich, dass die umfassende finanzielle Expertise und Führungserfahrung von Ihrskog in börsennotierten Unternehmen die Strategie von Vitrolife für nachhaltiges profitables Wachstum unterstützen wird.
- Appointment of experienced CFO with international expertise
- New CFO brings leadership experience from listed companies
- Strong educational background with master's in business administration
- 6-month transition period before new CFO takes office
"We are delighted to welcome Pär Ihrskog to the Vitrolife Group as CFO. His extensive financial expertise, combined with a proven track record of leadership in listed companies, brings valuable strategic and operational insight that will support the company in driving sustainable profitable growth," says Bronwyn Brophy O'Connor, CEO.
Helena Wennerström will remain as acting CFO until Pär takes office.
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor, CEO
The information was submitted for publication, through the agency of the contact persons set out above, at 10-04-2025 12:00 CET.
Contact:
Amelie Wilson, Investor Relations, awilson@vitrolife.com
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
The Vitrolife Group appoints Pär Ihrskog as the new Chief Financial Officer |
View original content:https://www.prnewswire.com/news-releases/the-vitrolife-group-appoints-par-ihrskog-as-the-new-chief-financial-officer-302425540.html
SOURCE Vitrolife AB (publ)